TRIAL DATA
Cetuximab Rechallenge Tested Against Regorafenib in RAS Wild-Type mCRCA single-center randomized trial evaluated cetuximab plus irinotecan rechallenge versus regorafenib in RAS wild-type, microsatellite-stable metastatic colorectal cancer patients who had previously responded to then progressed off cetuximab, with progression-free survival as the primary endpoint. (BMC Cancer)